AASM: Zepbound Approval for OSA a Positive Development for Patients and Clinicians

Zepbound Gets Green Light for Obesity-Driven Sleep Apnea

The US Food and Drug Administration’s recent approval of Zepbound (tirzepatide) marks a significant milestone in the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults grappling with obesity. This green signal, which Eli Lilly announced on Dec 20, 2024, received applause from the American Academy of Sleep Medicine (AASM) for providing a fresh option for tackling this sleep disorder. The AASM noted that this announcement is good news for patients and clinicians seeking an extra helping hand against OSA.

However, the AASM underscores that Zepbound is exclusively useful for managing obesity-related sleep apnea, clarifying that factors beyond excess weight, such as jaw and upper airway anatomy, might also play a role in this condition. While Zepbound can alleviate the severity of OSA, it may not be a cure-all. The AASM advises that incorporating additional treatments with Zepbound could benefit certain patients and mentions that maintaining weight loss over time is crucial for continued improvements in sleep apnea symptoms.

While the approval of Zepbound offers hope, the AASM also wants to emphasize that the drug comes with its fair share of potential risks and side effects, as detailed in its FDA-approved label.

For individuals weighing their options, patients with sleep apnea can seek guidance from sleep centers accredited by the AASM and consult board-certified sleep medicine physicians to determine the appropriateness of Zepbound for their conditions. The AASM offers a directory to help locate accredited sleep centers and professionals.

Photo by Oleschwander on Dreamstime

By following the latest news and developments in sleep medicine, patients can stay informed and make well-informed decisions about their health.